SI9600050B - Substituted benzenesulphonyl ureas and thioureas, processes for the preparation thereof and use of pharmaceutical preparations on the basis of these compounds as well as medicines containing them - Google Patents

Substituted benzenesulphonyl ureas and thioureas, processes for the preparation thereof and use of pharmaceutical preparations on the basis of these compounds as well as medicines containing them Download PDF

Info

Publication number
SI9600050B
SI9600050B SI9600050A SI9600050A SI9600050B SI 9600050 B SI9600050 B SI 9600050B SI 9600050 A SI9600050 A SI 9600050A SI 9600050 A SI9600050 A SI 9600050A SI 9600050 B SI9600050 B SI 9600050B
Authority
SI
Slovenia
Prior art keywords
carbon atoms
alkyl
hydrogen
formula
cycloalkyl
Prior art date
Application number
SI9600050A
Other languages
English (en)
Other versions
SI9600050A (en
Inventor
Heinrich Englert
Uwe Gerlach
Dieter Mania
Heinz Goegelein
Joachim Kaiser
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19505398A external-priority patent/DE19505398A1/de
Priority claimed from DE19522920A external-priority patent/DE19522920A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of SI9600050A publication Critical patent/SI9600050A/sl
Publication of SI9600050B publication Critical patent/SI9600050B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/58—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

  1. I Patentni zahtevki l. Substituirane benzensulfonilsečnine in -tiosečnine s formulo I
    R(3) N R(4) kjer pomenijo: R(l) vodik, alkil z 1, 2, 3, 4, 5, 6 ali 7 C-atomi, cikloalkil s 3, 4, 5, 6 ali 7 C-atomi; R(2) vodik, alkil z 1, 2, 3, 4, 5 ali 6 C-atomi, cikloalkil s 3, 4, 5 ali 6 C-atomi, ali (Ci-Cg)-verigo, v kateri je n C-atomov nadomeščenih s heteroatorru, npr. O, N, S (z n = 1-4), F, Cl; R(3) H, alkil z 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ali 12 C-atomi, cikloalkil s 3, 4, 5, 6, 7, 8, 9 ali 10 C-atomi, fluoralkil z 1, 2, 3, 4, 5 ali 6 C-atomi, fluorcikioalkil s 3, 4, 5 ali 6 C-atomi, ali (Ci-Cio)-verigo, v kateri je n C-atomov nadomeščenih s heteroatomi, npr. O, N, S, (n = 1, 2, 3 ali 4), R(4) vodik, alkil z 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ali 12 C-atomi, cikloalkil s 3, 4, 5, 6, 7, 8, 9 ali 10 C-atomi, fluoroalkil z 1, 2, 3, 4, 5 ali 6 C-atomi, fluorcikioalkil s 3, 4, 5 ali 6 C-atomi, ali (C[-C10)-verigo, v kateri je n C-atomov nadomeščenih s heteroatomi, npr. O, N, S, (n = 1, 2, 3 ali 4); ali R(3) m R(4) skupaj tvorita (Ch^-s-obroč, v katerem je lahko ena ali več izmed CH2-skupin nadomeščenih s heteroatomi; E kisik ali žveplo; X kisik ali žveplo; Y [CR(5)R(5')]m; R(5) in R(5) neodvisno drug od drugega vodik ali alkil z 1 ali 2 C-atomoma; pri čemer so členi [CR(5)R(5')] enaki ali različni; m 1, 2, 3 ali 4; kot tudi njihove farmacevtsko prenesljive soli. 2
  2. 2. Spojina s formulo I po zahtevku 1, označena s tem, da v njej pomenijo: R(l) vodik, alkil z 1, 2, 3, 4, 5, 6 ali 7 C-atomi, cikloalkil s 3, 4, 5, 6 ali 7 C-atomi; R(2) vodik, F, Cl, alkil z 1, 2, 3, 4, 5 ali 6 C-atomi, cikloalkil s 3, 4, 5 ali 6 C-atomi, ali (C2-C7)-verigo, v kateri so 1, 2, 3 ali 4 CH2-skupine nadomeščene s heteroatomi, npr. O, N ali S R(3) in R(4) enaka ali različna vodik, alkil z 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ali 12 C-atomi, cikloalkil s 3, 4, 5, 6, 7, 8, 9 ali 10 C-atomi, fluoralkil z 1, 2, 3, 4, 5 ali 6 C-atomi, fluorcikloalkil s 3, 4, 5 ali 6 C-atomi, ali (Ci-Cio)-verigo, v kateri so 1, 2, 3 ali 4 CH2-skupine nadomeščene s heteroatomi O, S ali NH; ali R(3) in R(4) skupaj (CH2)2_8, kjer je lahko ena izmed CH2-skupin nadomeščena s heteroatomom O, S ali NH; E kisik ali žveplo; X kisik ali žveplo; Y [CR(5)R(5')]m; R(5) in R(5’) neodvisno drug od drugega vodik ali alkil z 1 ali 2 C-atomoma; pri čemer so členi [CR(5)R(5')] enaki ali različni; m 1, 2, 3 ali 4; kot tudi njihove farmacevtsko prenesljive soli.
  3. 3. Spojina s formulo I po vsaj enem od zahtevkov 1 ali 2, označena s tem, da v njej pomenijo: R(l) vodik, alkil z 1, 2, 3 ali 4 C-atomi, cikloalkil s 3, 4, 5, 6 ali 7 C-atomi; R(2) F, Cl, alkil z 1, 2, 3 ali 4 C-atomi, ali (C2-C7) -verigo, kjer so 1, 2, 3 ali 4 CH2-skupine nadomeščene heteroatomi O, S ali NH; R(3) in R(4) enaka ali različna vodik, alkil z 1, 2, 3, 4, 5, 6, 7, 8, 9 ali 10 C-atomi, cikloalkil s 3, 4, 5 ali 6 C-atomi, ali (CrCi0) verigo, kjer so 1, 2, 3 ali 4 CH2 skupine nadomeščene s heteroatomi O, S ali NH; ali 3 «! e R(3) in R(4) skupaj (CH2)2-7, kjer je ena izmed CH2-skupin lahko nadomeščena s heteroatomi O, S, NH; E kisik ali žveplo; X kisik ali žveplo; Y [CR(5)R(5')]m; R(5) m R(5') neodvisno drug od drugega vodik ali alkil z 1 ali 2 C-atomoma, pri čemer so členi [CR(5)R(5')] enaki ali različni; m 1, 2, 3 ali 4; kot tudi njihove farmacevtsko prenesljive soli.
  4. 4) I I kjer imajo R(2), R(3), R(4), X, in Y v zahtevku 1 navedene pomene in M predstavlja alkalijski ali zemljoalkalijski ion, presnovimo z R(l)-substituiranim izocianatom s formulo IV R(l) - N = C = O IV, kjer ima R(l) v zahtevku 1 navedeni pomen, v substituirano benzensulfonilsečnino la; ali da (b) benzensulfonilsečnino s formulo la
    I Q pripravimo iz aromatskega benzensulfonamida II ali njegove soli III z R(l)-substituiranim trikloracetamidom s formulo V Cl/:-C(C=0)NH-R(l) 7 v prisotnosti baze; ali da (c) benzensulfoniltiosečnino Ib
    I b pripravimo iz benzensulfonamida II ali njegove soli III in R(l)-substituiranega tioizocianata VI R(1)-N=C=S VI ali da (d) benzensulfonilsečnino s formulo la pripravimo s reakcijo presnove iz benzensulfoniltiosečnine s formulo Ib; ali da (e) benzensulfonilsečnino la pripravimo s presnovo amina s formulo R(1)-NH2 s benzensulfonilizocianatom s formulo VII n n R(J)
    V I I ali da (f) benzensulfoniltiosečnino Ib pripravimo s presnovo amina s formulo z benzensulfonilizotiocianatom s formulo VIII 8
    ali da (g) benzensulfonilsečnino la pripravimo iz benzensulfonilsečnine s formulo IX
    in R(3)R(4)NH s pomočjo dehidratacijskega sredstva ali aktiviranja s pomočjo halogenidov karboksilne kisline oz. tvorbo mešanih anhidridov; ali da (h) benzensulfoniltiosečnino Ib pripravimo iz benzensulfoniltiosečnine s formulo X
    in R(3)R(4)NH s pomočjo dehidratacijskega sredstva ali z aktiviranjem s pomočjo halogenidov karboksilne kisline oz. tvorbo mešanih anhidridov. « r r · « « p . * OjO Ο Ο ο » '·> Οβ 3 • ρ «e«r r7,->rri *»> Ί *» • r r r r, r · r r r »> f 1 >·» )Ί ·> j > e-·'··^ r · r r* > ’ ‘ ’ 1 f· r r r rr· Λ ’ ' 9
    4. Spojine s formulo I po zahtevku 1, označene s tem, da v njih pomenijo: R( 1) vodik, alkil z 1, 2, 3, 4, 5, 6 ali 7 C-atomi, cikloalkil s 3, 4, 5, 6 ali 7 C-atomi; R(2) alkoksi z 1, 2, 3, 4, 5 ali 6 C-atomi ali merkaptoalkil z 1, 2, 3, 4, 5 ali 6 C-atomi; R(3) H, alkil z 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ali 12 C-atomi, cikloalkil s 3, 4, 5, 6, 7, 8, 9 ali 10 C-atomi fluoralkil z 1, 2, 3, 4, 5 ali 6 C-atomi, fluorcikloalkil s 3, 4, 5 ali 6 C-atomi ali (Ci-Ci0) verigo, v kateri je n C-atomov nadomeščenih s heteroatomi, npr. O, N, S, (n = 1, 2, 3 ali 4); R(4) vodik, alkil z 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ali 12 C-atomi, cikloalkil z 3, 4, 5, 6, 7, 8, 9, ali 10 C-atomi, fluoralkil z 1, 2, 3, 4, 5 ali 6 C-atomi, fluorcikloalkil s 3, 4, 5 ali 6 C-atomi ali (Ci-Cio) verigo, v kateri je n C-atomov nadomeščenih s heteroatomi, npr. O, N, S, (n = 1, 2, 3 ali 4); ali R(3) in R(4) skupaj tvorita (CH2)2-8-obroč, v katerem je lahko ena ali več CH2-skupin nadomeščenih s heteroatomi; E kisik ali žveplo; X kisik ali žveplo; Y [CR(5)R(5')]m; R(5) in R(5') neodvisno drug od drugega vodik ali alkil z 1 ali 2 C-atomoma; 4 pri čemer so členi [CR(5)R(5')] enaki ali različni; m 1, 2, 3 ali 4; kot tudi njihove farmacevtsko prenesljive soli.
  5. 5. Spojina s formulo I po vsaj enem od zahtevkov 1 do 4, označena s tem, da v njej pomenijo: R(l) vodik, alkil z 1, 2, 3 ali 4 C-atomi, cikloalkil s 3 ali 4 C-atomi; R(2) metoksi ali etoksi; R(3) m R(4) enaka ali različna vodik, alkil s 3, 4, 5, 6, 7 ali 8 C-atomi, cikloalkil s 3, 4, 5 ali 6 C-atomi ali (C3.8H7.i7)-skupmo, kjer so 1, 2, 3 ali 4 CH2-skupine nadomeščene s heteroatomi O, S, NH; ali R(3) in R(4) skupaj (CH2)2-8-skupino, kjer je lahko ena izmed CH2-skupin nadomeščena s heteroatomi O, S, NH; E žveplo ali kisik; X kisik; Y [CR(5)R(5')]m; R(5) in R(5’) neodvisno drug od drugega vodik ali alkil z 1 ali 2 C-atomoma; pri čemer so členi [CR(5)R(5')] enaki ali različni; m 1 ali 2, kot tudi njihove farmacevtsko prenesljive soli.
  6. 6. Spojina s formulo I po vsaj enem od zahtevkov 1 do 5, označena s tem, da v njej pomenijo: R(l) vodik, alkil z 1, 2 ali 3 C-atomi ali cikloalkil s 3 C-atomi; R(2) metoksi ali etoksi; R(3) in R(4) 5 enaka ali različna vodik, alkil s 5, 6, 7 ali 8 C-atomi, cikloalkil s 5 ali 6 C-atomi ali (C5.8Hii.i7)-skupino, kjer so 1, 2, 3 ali 4 CH2-skupine nadomeščene s heteroatomi O, S, NH; ali R(3) m R(4) skupaj (CH2)s.g, kjer je lahko ena izmed CH2-skupin nadomeščena s heteroatomi O, S, NH; E žveplo ali kisik; X kisik; Y [CR(5)R(5')]m; R(5) m R(5') neodvisno drug od drugega vodik ali metil; pri čemer so členi [CR(5)R(5')] enaki ali različni; m 1 ali 2, kot tudi njihove farmacevtsko prenesljive soli.
  7. 7. Spojina s formulo I po vsaj enem od zahtevkov 1 do 6, označena s tem, da v njej pomenijo: R(l) vodik, alkil z 1, 2 ali 3 C-atomi ali cikloalkil s 3 C-atomi; R(2) metoksi ali etoksi; R(3) vodik; R(4) alkil s 5, 6,1 ali 8 C-atomi, cikloalkil s 5 ali 6 C-atomi ali (Cs.gHi i„n)-skupino, v kateri so 1, 2, 3 ali 4 CH2-skupine nadomeščene s heteroatomi O, S, NH; E žveplo ali kisik; X kisik; Y [CR(5)R(5')]m; R(5) in R(5') neodvisno drug od drugega vodik ali metil; pri čemer so členi [CR(5)R(5')] enaki ali različni; m 1 ali 2, kot tudi njihove farmacevtsko prenesljive soli.
  8. 8. 6 Postopek za pripravo spojine s formulo I po zahtevku 1, označen s tem, da (a) sulfonamid s formulo II 8. 6
    ali njegovo sol s formulo III
  9. 9. Uporaba spojine I po zahtevku 1 za pripravo zdravila za zdravljenje motenj srčnega ritma.
  10. 10. Uporaba spojine I po zahtevku 1 za pripravo zdravila za preprečevanje nenadne smrti srca.
  11. 11. Uporaba spojine I po zahtevku 1 za pripravo zdravila za zdravljenje ishemičnih stanj srca.
  12. . 12. Uporaba spojine I po zahtevku 1 za pripravo zdravila za zdravljenje oslabljene moči srca.
  13. 13. Uporaba spojine I po zahtevku 1 za pripravo zdravila za izboljšanje srčne funkcije po transplantaciji srca.
  14. 14. Zdravilo, označeno s tem, da vsebuje učinkovito količino spojine s formulo I po enem ali več zahtevkih 1 do 7.
SI9600050A 1995-02-17 1996-02-16 Substituted benzenesulphonyl ureas and thioureas, processes for the preparation thereof and use of pharmaceutical preparations on the basis of these compounds as well as medicines containing them SI9600050B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19505398A DE19505398A1 (de) 1995-02-17 1995-02-17 Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und Verwendung pharmazeutischer Präparate auf Basis dieser Verbindungen sowie sie enthaltende Heilmittel
DE19522920A DE19522920A1 (de) 1995-06-23 1995-06-23 Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und Verwendung pharmazeutischer Präparate auf Basis dieser Verbindungen sowie sie enthaltende Heilmittel

Publications (2)

Publication Number Publication Date
SI9600050A SI9600050A (en) 1996-10-31
SI9600050B true SI9600050B (en) 2001-12-31

Family

ID=26012537

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9600050A SI9600050B (en) 1995-02-17 1996-02-16 Substituted benzenesulphonyl ureas and thioureas, processes for the preparation thereof and use of pharmaceutical preparations on the basis of these compounds as well as medicines containing them

Country Status (29)

Country Link
US (2) US5880155A (sl)
EP (1) EP0727417B1 (sl)
JP (1) JP3905573B2 (sl)
KR (1) KR100432259B1 (sl)
CN (1) CN1060162C (sl)
AR (1) AR002708A1 (sl)
AT (1) ATE199541T1 (sl)
AU (1) AU700254B2 (sl)
BR (1) BR9600779A (sl)
CA (1) CA2169696C (sl)
CZ (1) CZ291793B6 (sl)
DE (1) DE59606531D1 (sl)
DK (1) DK0727417T3 (sl)
ES (1) ES2155546T3 (sl)
FI (1) FI120391B (sl)
GR (1) GR3035710T3 (sl)
HR (1) HRP960076B1 (sl)
HU (1) HU226462B1 (sl)
IL (1) IL117152A (sl)
MY (1) MY115795A (sl)
NO (1) NO305795B1 (sl)
NZ (1) NZ280992A (sl)
PL (1) PL181792B1 (sl)
PT (1) PT727417E (sl)
RU (1) RU2198872C2 (sl)
SI (1) SI9600050B (sl)
SK (1) SK282131B6 (sl)
TR (1) TR199600117A2 (sl)
TW (1) TW357141B (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
TR199901816T2 (xx) * 1997-01-29 1999-11-22 Pfizer Inc S�lfonil �re t�revleri, bunlar�n interl�kin-1 aktivitesinin kontrol�nde kullan�mlar�.
DE19832009A1 (de) 1998-07-16 2000-01-20 Hoechst Marion Roussel De Gmbh 2,5-Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharamazeutische Präparate
DE10129704A1 (de) * 2001-06-22 2003-01-02 Aventis Pharma Gmbh Verwendung von Benzolsulfonyl(thio)harnstoffen in der Behandlung des septischen Schocks
ES2333979T3 (es) * 2004-11-22 2010-03-03 Eli Lilly And Company Potenciadores de los receptores del glutamato.
CN104649945B (zh) * 2015-02-05 2017-02-22 中国农业大学 一种磺酰脲类、磺酰胺基甲酸酯类化合物的制备方法
WO2023020412A1 (zh) * 2021-08-16 2023-02-23 中国科学院上海药物研究所 磺酰脲化合物、制备方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1198354B (de) * 1963-09-25 1965-08-12 Hoechst Ag Verfahren zur Herstellung von Benzol-sulfonylharnstoffen
DE1185180B (de) * 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
BE754454A (fr) * 1969-08-06 1971-02-05 Bayer Ag Nouveaux composes hypoglycemiques du type d'arylsulfonylurees et d'arylsulfonylsemicarbazides contenant des groupes carbonamide
DE2413514C3 (de) * 1974-03-21 1982-03-04 Hoechst Ag, 6000 Frankfurt N-Acylaminoathylbenzolsulfonyl-N'-methylharnstoffe, Verfahren zu ihrer Herstellung und deren Verwendung
DK0612724T3 (da) * 1993-02-23 1997-06-16 Hoechst Ag Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til deres fremstilling og deres anvendelse som farmaceutika

Also Published As

Publication number Publication date
DK0727417T3 (da) 2001-07-09
SK282131B6 (sk) 2001-11-06
US5977177A (en) 1999-11-02
NO960628D0 (no) 1996-02-16
EP0727417B1 (de) 2001-03-07
CA2169696A1 (en) 1996-08-18
KR960031432A (ko) 1996-09-17
ATE199541T1 (de) 2001-03-15
PL181792B1 (pl) 2001-09-28
US5880155A (en) 1999-03-09
AR002708A1 (es) 1998-04-29
DE59606531D1 (de) 2001-04-12
EP0727417A1 (de) 1996-08-21
BR9600779A (pt) 1997-12-23
FI960688A (fi) 1996-08-18
IL117152A (en) 2002-07-25
RU2198872C2 (ru) 2003-02-20
CZ291793B6 (cs) 2003-05-14
NZ280992A (en) 1996-10-28
FI120391B (fi) 2009-10-15
HU9503877D0 (en) 1996-02-28
CN1060162C (zh) 2001-01-03
AU700254B2 (en) 1998-12-24
JP3905573B2 (ja) 2007-04-18
NO305795B1 (no) 1999-07-26
JPH08245556A (ja) 1996-09-24
FI960688A0 (fi) 1996-02-15
SI9600050A (en) 1996-10-31
PL312530A1 (en) 1996-08-19
ES2155546T3 (es) 2001-05-16
HU226462B1 (en) 2008-12-29
CA2169696C (en) 2008-09-02
TR199600117A2 (tr) 1996-10-21
HRP960076B1 (en) 2001-12-31
KR100432259B1 (ko) 2004-09-18
NO960628L (no) 1996-08-19
TW357141B (en) 1999-05-01
CZ43596A3 (en) 1996-09-11
GR3035710T3 (en) 2001-07-31
AU4555996A (en) 1996-08-29
MY115795A (en) 2003-09-30
IL117152A0 (en) 1996-06-18
HRP960076A2 (en) 1997-12-31
HUT73982A (en) 1996-10-28
SK21296A3 (en) 1996-10-02
CN1134415A (zh) 1996-10-30
PT727417E (pt) 2001-08-30

Similar Documents

Publication Publication Date Title
CN102803203B (zh) 卤代烷基杂芳基苯甲酰胺化合物
GB9624482D0 (en) Chemical compounds
HUP0402360A2 (hu) Poliaminok alkalmazása progenitor sejtek és/vagy őssejtek számának növelésére alkalmas gyógyszerkészítmény előállítására
IE870013L (en) Azabicyclo (3.2.1. or 2.2.2.) oct-3-yl-indole derivatives
EP0498466A1 (en) Indazole-3-carboxamide and -3-carboxylic acid derivatives
KR890008155A (ko) 신규인 유도체, 그 제조방법 및 의약에서의 사용
SI9600050B (en) Substituted benzenesulphonyl ureas and thioureas, processes for the preparation thereof and use of pharmaceutical preparations on the basis of these compounds as well as medicines containing them
SI9600049B (en) Substituted benzenesulphonyl ureas and thioureas, process for the preparation thereof, use thereof as medicine or as diagnostic as well as medicine containing them
HUP0104994A2 (hu) Szubsztituált (amino-imino-metil- vagy amino-metil)-benzo-heteroaril-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP0544760B1 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
SI9600053B (en) Substituted benzensulphonyl ureas and thioureas, process for the preparation thereof and use thereof for the preparation of pharmaceutical preparations as well as pharmaceutical preparations containing them
SI9600040B (en) Substituted benzensulphonyl ureas and thioureas, process for the preparation thereof and use thereof for the preparation of pharmaceutical preparations as well as pharmaceutical preparations containing them
IL43722A (en) 2-aminomethyleneindanones and pharmaceutical compositions containing them
EP0134582A3 (en) Novel peptides and process for preparing the same and pharmaceutical composition
DE3786256D1 (de) Antifolat-mittel.
RU96102852A (ru) Замещенные бензолсульфонилмочевины и - тиомочевины, способ их получения, содержащая их фармацевтическая композиция и способ ее получения
SE7907689L (sv) Nya hydroxamsyraforeningar, sett for deras framstellning samt anvendning av dessa foreningar som lekemedel
US4085218A (en) Elevating mood in geriatric patients
ATE21693T1 (de) Substituierte pyrimid-2-one, ihre salze, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten.
GB1481948A (en) 2-(disubstituted-amino)-4-phenyl-imidazolines and their use in pharmaceutical compositions
GB1031165A (en) Guanidines, isoureas and isothioureas
DE3371514D1 (en) Thiazole derivatives, process for their preparation and pharmaceutical compositions containing them
GB1573621A (en) Acylated 6-methyl-8a-amino-ergoline i compounds
ES8301996A1 (es) Procedimiento para la preparacion de nuevas penicilinas .
TH9830EX (th) อนุพันธ์ต่างๆ ของพิร์โรโล (2, 1 - b) ไธอะโซล

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20121017